IL-12 gene-deficient C57BL/6 mice are susceptible to Leishmania donovani but have diminished hepatic immunopathology

European Journal of Immunology

Volumn 30, Issue 3, 2000, Pages 834-839

  Satoskar, Abhay R ^a   Rodig, Scott ^c   Telford III, Sam R ^a   Satoskar, Anjali A ^b   Ghosh, Sudip K ^a   Von Lichtenberg, Franz ^c   David, John R ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c NONE

Author keywords

IL 12; Leishmania; Liver

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 4;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; HEPATITIS; HEPATOSPLENOMEGALY; IMMUNITY; IMMUNOPATHOLOGY; IMMUNOSTIMULATION; KNOCKOUT MOUSE; LEISHMANIA DONOVANI; LIVER GRANULOMA; MOUSE; NONHUMAN; PARASITIC LIVER DISEASE; PRIORITY JOURNAL; SPLEEN CELL; SPLEEN DISEASE; VISCERAL LEISHMANIASIS;

ANIMALS; FEMALE; INTERFERON TYPE II; INTERLEUKIN-12; INTERLEUKIN-4; KINETICS; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; LIVER; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; SPLEEN; T-LYMPHOCYTES;

EID: 0033999966     PISSN: 00142980     EISSN: None     Source Type: Journal    
DOI: 10.1002/1521-4141(200003)30:3<834::AID-IMMU834>3.0.CO;2-9     Document Type: Article

References (19)

1. Alexander, J. and Russell, D. G., The interaction of Leishmania species with macrophages. Adv. Parasitol. 1992. 31: 175-254.
2. Liew, F. Y. and O'Donell, C. A., Immunology of leishmaniasis. Adv. Parasitol. 1993. 32: 161-258.
3. Pearson, R. D. and Wilson, M. E., Host defenses against prototypical intracellular protozoans, the Leishmania. In Walzer, P. D. and Genta, R. M. (Eds.) Parasitic Infections in the Compromised Host. Marcel Dekker, New York 1989, p. 31.
4. Trinchieri, G., Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu. Rev. Immunol. 1995. 13: 251-276.
5. Murray, H. W. and Hariprashad, J., Interleukin 12 is effective treatment for an established systemic intracellular infection: experimental visceral leishmaniasis. J. Exp. Med. 1995. 181: 387-391.
6. Murray, H. W., Endogenous interleukin-12 regulates acquired resistance in experimental visceral leishmaniasis. J. Infect. Dis. 1997. 175: 1477-1479.
7. Engwerda, C. R., Murphy, M. L., Cotterell, S. E., Smelt, S. C. and Kaye, P. M., Neutralization of IL-12 demonstrates organ-specific phases in the control of Leishmania donovani. Eur. J. Immunol. 1998. 28: 669-680.
8. Murray, H. W., Effect of continuous administration of interferon-γ in experimental visceral leishmaniasis. J. Infect. Dis. 1990. 161: 992-994.
9. Squires, K. E., Schreiber, R. D., McElrath, M. J., Rubin, B. Y., Anderson, S. L. and Murray, H. W., Experimental visceral leishmaniasis: role of endogenous IFN-γ in host defense and tissue granulomatous response. J. Immunol. 1989. 143: 4244-4249.
10. Murray, H. W., Squires, K. E., Miralles, C. D., Stoeckle, M. Y., Granger, A. M., Granelli Piperno, A. and Bogdan, C., Acquired resistance and granuloma formation in experimental visceral leishmaniasis. Differential T cell and lymphokine roles in initial versus established immunity. J. Immunol. 1992. 148: 1858-1863.
11. Taylor, A. P. and Murray, H. W., Intracellular antimicrobial activity in the absence of interferon-gamma: effect of interleukin-12 in experimental visceral leishmaniasis in interferon-gamma gene-disrupted mice. J. Exp. Med. 1997. 185: 1231-1239.
12. Murray, H. W., Hariprashad, J. and Coffman, R. L., Behavior of visceral Leishmania donovani in an experimentally induced T helper cell 2 (Th2)-associated response model. J. Exp. Med. 1997. 185: 867-874.
13. Scharton-Kersten, T., Afonso, L. C., Wysocka, M., Trinchieri, G. and Scott, P., IL-12 is required for natural killer cell activation and subsequent T helper 1 cell development in experimental leishmaniasis. J. Immunol. 1995. 154: 5320-5330.
14. Sypek, J. P., Chung, C. L., Mayor, S. E. H., Subramanyam, J. M., Goldman, S. J., Sieburth, D. D., Wolf, S. F., Schaub, R. G., Resolution of cutaneous leishmaniasis: interleukin 12 initiates a protective T helper type 1 immune response. J. Exp. Med. 1993. 177: 1797-1802.
15. Heinzel, F. P., Schoenhaut, D. S., Rerko, R. M., Rosser, L. E. and Gatley, M. K., Recombinant interleukin-12 cures mice infected with Leishmania major. J. Exp. Med. 1993. 177: 1505-1509.
16. Mattner, F., Magram, J., Ferrante, J., Launois, P., Di Padova, K., Behin, R., Gatley, M. K., Louis, J. A. and Alber, G., Genetically resistant mice lacking interleukin-12 are susceptible to infection with Leishmania major and amount a polarized Th2 cell response. Eur. J. Immunol. 1996. 26: 1553-1559.
17. Satoskar, A., Bluethmann, H. and Alexander, J., Disruption of the murine interleukin-4 gene inhibits disease progression during Leishmania mexicana infection but does not increase control of Leishmania donovani infection. Infect. Immun. 1995. 63: 4894-4899.
18. Kaye, P. M., Curry, A. J., and Blackwell, J. M., Differential production of Th1 and Th2 derived cytokines does not determine the genetically controlled or vaccine induced rate of cure in murine visceral leishmaniasis. J. Immunol. 1991. 146: 2763-2770.
19. Stamm, L. M., Raisanen-Sokolowski, A., Okano, M., Russell, M. E., David, J. R. and Satoskar, A. R., Mice with STAT6-targeted gene disruption develop a Th1 response and control cutaneous leishmaniasis. J. Immunol. 1999. 161: 6180-6188.